Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Cue Biopharma Inc

CUE ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$34.20

▲ +10.04%

Market Cap $138.36M · Vol 33.14K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$138.36M

Micro Cap

Div Yield

N/A

EPS Growth

+20.95%

YoY

RSI (14)

53.99

Momentum

Beta

2.52

vs Market

52W High

$45.23

24.39% below

52W Low

$4.97

587.58% above

Volume

33.14K

Avg 40.08K

P/B

1.12

Price-to-book

ROE

N/A

Return on equity

Free Float

79.79%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Cue Biopharma Inc (CUE) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CUE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+26.11%

+9.34%

+35.02%

+271.82%

YTD

+273.28%

+44.30%

-59.43%

-89.74%

Financials & Valuation

TTM · Annual

Total Revenue	$27.47M
Net Income	$-26,602,000.00
Revenue Growth (YoY)	+166.66%
Gross Margin	100.00%
Operating Margin	-96.56%
Net Profit Margin	-96.85%
ROE	N/A
ROA · ROIC	-70.16% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	1.05
P/B	1.12
P/FCF	N/A
EPS Growth	+20.95%
Outstanding Shares	4.05M

Technical Indicators

50-Day SMA	$29.53
200-Day SMA	$18.37
RSI (14)	53.99
Beta	2.52
52-Week High	$45.23
52-Week Low	$4.97

Volume Today	33.14K
Avg Daily Volume (30D)	40.08K
Relative Volume	0.83x
Volatility (10D)	65.67
Volatility (30D)	108.62
Free Float	79.79%

Analyst Consensus

BUY

Current Price $34.20

Mean Target $115.00

52W Low$4.97 52W High$45.23

Current

Target

$4.97 $45.23

Current Analyst target

+236.26% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00FVMPFP5

ISINUS22978P2056

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateAug 13, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. Its proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells) and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation. Its lead programs include drug product candidates designed to: CUE-400 series (Autoimmune Diseases) enhance regulatory T cells (Tregs) with a novel mechanism to proliferate, generate Tregs, and restore immune balance (CUE-401 for autoimmune conditions);CUE-500 series (Targeted Cell Depletion) redirect antiviral T cells to target eliminate pathogenic cells (CUE-501 for autoimmune B cell depletion); and CUE-100 series (Oncology) selectively activate tumor-specific T cells.